Lewis J Gazzard

This inventor holds 39 USPTO granted patents and 18 published patent applications, plus 4 CIPO patents and 23 EPO patents, primarily in Cancer Therapeutics. Top assignees: Genentech, Inc., Array Biopharma Inc., Newlink Genetics Corporation. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lewis J Gazzard. Retrieved from https://idiyas.com/inventor/lewis-j-gazzard

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 39 (Patent Applications = 18)

% Patents Active = 87.2

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 23 (Patent Applications = 27)

Average Co-Inventor Count = 6.8

ph-index = 6

Forward Citations = 218(Granted Patents)

Location History:

Skipton, GB (2007)
South San Francisco, CA (US) (2015 - 2023)
Belmont, CA (US) (2007 - 2024)

Company Filing History:

Newlink Genetics Corporation

where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

TDO2 Inhibitors

Isoquinoline Compounds

Serine/Threonine Kinase Inhibitors

Naphthyridine Compounds

Azaindoles

IAP Inhibitors

8-Aminoisoquinoline

Diazacarbazoles

Substituted Quinazolines

Heterocyclic Compounds

Acylsulfamide Inhibitors

Antibody Drug Conjugates

39 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12583858 - TDO2 inhibitors (2026-03-24),

2. 12473301 - Isoquinoline compounds for the treatment of cancer (2025-11-18),

3. 12378249 - Isoquinoline compounds and uses thereof (2025-08-05),

4. 12338256 - Aza-tetracyclic oxazepine compounds and uses thereof (2025-06-24),

5. 12297210 - Naphthyridine compounds and uses thereof (2025-05-13),

6. 12152040 - Tert-butyl (s)-2-(4-(phenyl)-6H-thieno[3, 2-f][1, 2, 4]triazolo[4, 3-a] [1,4]diazepin-6-yl) acetate derivatives and related compounds as bromodomain BRD4 inhibitors for treating cancer (2024-11-26),

7. 11963994 - Inhibitors of IAP (2024-04-23),

8. 11944606 - Azaindoles as inhibitors of HPK1 (2024-04-02),

9. 11827639 - TDO2 and IDO1 inhibitors (2023-11-28),

10. 11612606 - 8-aminoisoquinoline compounds and uses thereof (2023-03-28),

11. 11603373 - TDO2 and IDO1 inhibitors (2023-03-14),

12. 11566003 - Isoquinolines as inhibitors of HPK1 (2023-01-31),

13. 11242344 - (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof (2022-02-08),

14. 11096982 - Inhibitors of IAP (2021-08-24),

15. 11034692 - Naphthyridines as inhibitors of HPK1 (2021-06-15),

Title: Unveiling the Genius of Lewis Gazzard: Innovating with Azaindoles at Genentech, Inc.

Introduction: Lewis Gazzard, a brilliant inventor based in Belmont, CA (US), has made significant contributions in the field of pharmaceuticals with his groundbreaking patent on Azaindoles as inhibitors of HPK1.

Latest Patents: Lewis Gazzard holds 1 patent for Azaindole compounds that act as potent inhibitors of HPK1, showcasing his expertise in developing novel therapeutic solutions for HPK1-dependent disorders and immune response enhancement.

Career Highlights: With his innovative work at Genentech, Inc., Lewis Gazzard has demonstrated a keen understanding of molecular pharmacology and drug development, paving the way for cutting-edge treatments in the biopharmaceutical industry.

Collaborations: Alongside accomplished colleagues like Timothy Heffron and Sushant Malhotra, Lewis Gazzard has synergized his talents to drive impactful research initiatives, fostering a collaborative environment where innovative ideas flourish.

Conclusion: Lewis Gazzard's inventive spirit and dedication to advancing medical science underscore his role as a visionary inventor at Genentech, Inc., leaving an indelible mark on the landscape of pharmaceutical innovation.

Profile summary based on public USPTO records.